Research aims to provide physicians more targeted approach to treating ER+ breast can
 

The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

More...

Re: Research aims to provide physicians more targeted approach to treating ER+ breast
 

The link didn't work for me.

Re: Research aims to provide physicians more targeted approach to treating ER+ breast
 

Driving force behind I-SPY2 trial is to reduce size of phaseIII trials in order to get new, effective drugs approved for early BC indications in most expedient fashion.
http://www.clinicaltrials.gov/ct2/sh...2+t-dm1&rank=1

Re: Research aims to provide physicians more targeted approach to treating ER+ breast
 

I noted Phase II is only 6 months from completion - Feb 2014. Interesting. I look forward to seeing the data.